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Abstract
Background: The effect of progesterone elevation (PE) on the day of human chorionic gonadotropin (hCG)
administration on the pregnancy outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles
is a matter of ongoing debate. The replacement of cleavage-stage embryos with blastocyst-stage embryos for
transfer was proposed to avoid the possible impairment of PE in fresh cycles. This study aimed to assess the
association between PE on the day of human chorionic gonadotropin (hCG) administration and clinical pregnancy
rates (CPRs) in IVF/ICSI cycles with embryos transferred at different developmental stages (cleavage and blastocyst).
Moreover, a secondary aim was to determine the thresholds at which PE has a detrimental effect on CPRs.
Methods: This single-center retrospective cohort study included more than 10,000 patients undergoing day 3
cleavage-stage embryo transfer (ET) and 1146 patients undergoing day 5 blastocyst-stage embryo transfer (ET)
using gonadotropin and GnRH agonist for controlled ovarian stimulation.
Results: Serum PE was inversely associated with CPRs in both cleavage- and blastocyst-stage ET cycles. In the day 3
ET cycles, CPRs (progesterone levels < 0.5 ng/ml, 49.2 %) significantly declined when the progesterone
concentration reached 1.0 ng/ml (45.5 %) and decreased further when the progesterone concentration increased to
1.5 ng/ml (36.2 %). In the day 5 blastocyst-stage ET cycles, patients with serum progesterone levels ≥1.75 ng/ml
had significantly lower CPRs (31.3 % VS. 41.4 %, p < 0.001) compared to patients with serum progesterone
levels <1.75 ng/ml. The negative association of PE with CPRs was noted in both ET groups, even after adjusting
for confounders. Furthermore, the developmental stage of the transferred embryos was not linked to the effect
of PE on CPRs because the interaction between the developmental stage of the transferred embryos and PE
was not significant.
Conclusions: PE on the day of hCG administration is associated with decreased CPRs in GnRH agonist IVF/
intracytoplasmic sperm injection (ICSI) cycles regardless of the developmental stage of the transferred embryos
(cleavage versus blastocyst stage).
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Background
Despite the widespread use of gonadotropin-releasing hor-
mone (GnRH) analogues for pituitary down-regulation,
progesterone elevation (PE), which refers to an increase in
serum progesterone concentrations, still occurs at differ-
ent frequencies on the day of human chorionic gonado-
tropin (hCG) administration for final oocyte maturation in
fresh in vitro fertilization (IVF) cycles [1]. Moreover, the
question of whether PE on the day of hCG administration
affects the outcomes of IVF is still being debated [2–12].
Some studies have indicated that PE does not affect the
probability of pregnancy in IVF [2–4, 12]; however, other
studies have concluded that PE resulted in a decreased
probability of pregnancy [5–11]. The use of simple bivari-
ate analyses and arbitrary cut-off levels in most of these
studies may explain these varying results. Recently, a
large-sample meta-analysis confirmed the adverse effect of
PE on IVF pregnancy outcomes [1].
The precise endocrinological mechanism underlying
the adverse effects of PE is still unclear; however, oocyte
quality [13] and endometrial receptivity [14, 15] may play
roles in this process. The hypothesis regarding endomet-
rial receptivity is seemingly more convincing because of
the results of gene expression studies on the endometrium
[16, 17] and studies showing that the live birth rates of
women implanted with frozen-thawed embryos or donor
oocytes from fresh cycles did not significantly differ be-
tween those with PE and those without PE [1, 18].
Several strategies have been proposed to avoid the
possible detrimental effects of PE in fresh IVF cycles
[19, 20]. One strategy is to replace cleavage-stage em-
bryos with blastocyst-stage embryos prior to transfer
because evidence suggests that PE does not decrease
pregnancy rates in day 5 single blastocyst transfer cy-
cles [7, 21]. However, the reliability of these results has
not been confirmed, and some researchers have found
that PE can still impair IVF outcomes, even in blasto-
cyst transfers [8, 13, 22].
Hence, the aim of this study was to assess the associ-
ation between PE on the day of hCG administration and
the clinical pregnancy rates (CPRs) of GnRH agonist
IVF/intracytoplasmic sperm injection (ICSI) cycles with
the transfer of embryos at different developmental
stages. Moreover, a secondary aim was to determine the




This was a single-center retrospective cohort study. Pa-
tients who were undergoing IVF with gonadotropin and
a GnRH agonist for controlled ovarian stimulation were
enrolled from January 2010 to October 2014. A total of
10,864 patients were assigned to the day 3 embryo
transfer (ET) group undergoing cleavage-stage ET, and
1146 patients were assigned to the day 5 ET group
undergoing blastocyst-stage ET. The Ethics Committee
of the First Hospital of Zhengzhou University approved
the research protocol for this study.
The exclusion criteria were as follows: (i) individuals
in the first or second oocyte or sperm donation cycles
and (ii) couples in which either member had chromo-
somal abnormalities. Each patient was included in the
study only once, during either the first or second IVF/
ICSI cycle.
The following patient characteristics were evaluated:
age, basal follicle-stimulating hormone (bFSH) level,
body mass index (BMI), cause of infertility, duration of
infertility and type of infertility. Other measured param-
eters included the dose and type of gonadotropin; the
duration of gonadotropin administration; serum endo-
metrial thickness and P/E2/LH levels (on the hCG day);
and the numbers of retrieved oocytes, two pronuclear
(2PN) oocytes, 2PN cleavage embryos, available embryos
and transferred embryos. All data were collected from
computerized databases.
Controlled ovarian stimulation and embryo transfer
The selected protocols included a standard long GnRH
agonist protocol and a prolonged or modified prolonged
GnRH agonist protocol [23, 24]. Clinicians selected an
appropriate protocol for each patient on a case-by-case
basis based on patient characteristics.
Pituitary suppression was achieved by injecting triptor-
elin acetate (Decapeptyl® 0.1 mg [Ferring, Germany] or
Diphereline® 0.1/3.75 mg [Ipsen, France]) until the
serum levels of E2, follicle-stimulating hormone (FSH)
and LH were <30 mIU/mL, <5 mIU/mL and <5 mIU/
mL, respectively. Controlled ovarian stimulation was initi-
ated with several types of gonadotropin, with follicle
stimulating hormone (FSH) activity (Gonal-F® 75 IU
[Serono, Switzerland], Fostiman® 75 IU [IBSA, Switzerland],
or Puregon® 50 IU [N. V. Organon, Netherlands]) or
with FSH combined with luteinizing hormone (LH) ac-
tivity (hMG®, Livzon, China). In general, the initial dose
of gonadotropins, which ranged from 112.5 IU to 400 IU,
was based on the individual’s age, BMI, bFSH and re-
sponse during previous stimulated cycles and the presence
of polycystic ovary syndrome (PCOS).
After at least 4 days of stimulation, doses were ad-
justed based on the ovarian response, as evaluated
using ultrasonography and serum E2 measurement.
When more than three follicles reached 17 mm, hCG
was injected, and after 36–37 h, oocyte retrieval was
performed.
A grading criterion was used to evaluate the quality of
the cleavage-stage embryos [25]. Grade 1 and Grade 2
embryos with ≥6 symmetrical blastomeres of equal size
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were considered top-quality embryos. Generally, patients
with three or more top-quality cleavage-stage embryos
were likely to be candidates for blastocyst culture. A
scoring system developed by Gardner was applied for
blastocyst-stage embryo grading [26]. A blastocyst with a
grade ≥3BB was considered a top-quality embryo. Ac-
cording to national regulations, the number of embryos
per patient, and other individual requirements, 1–3 of
the best day 3 embryos or 1–2 of the best day 5 blasto-
cysts were selected for transfer. In addition, when the
progesterone level had increased to more than 2.5 ng/ml
before hCG, all embryos were frozen and transferred in
sequential frozen ET cycles.
Serum hormone measurements
Basal FSH was measured on days 2–4 of the menstrual
cycle before the IVF cycle began. Hormones, including
LH, E2 and P, were assessed during controlled ovarian
stimulation (once every 2–4 days at first and once a day
during the late follicular phase and on the day of hCG
administration in each cycle). All blood samples were
taken during fasting, generally between 6:30 and
7:30 am. We used an individual immunoanalyzer (Roche
Cobas e411; Roche Diagnostics, Mannheim, Germany)
and the same assays for all hormone measurements dur-
ing the entire study.
Serum progesterone levels were measured using an
electrochemiluminescence immunoassay with Progester-
one II (Cobas 12145383). The assay’s limit was 0.03 ng/
ml, and its sensitivity was 0.15 ng/ml. The intra-assay
and inter-assay coefficients of variation were 3.0 and
5.5 %, respectively.
Outcome variables
The CPR was the primary outcome. The presence of an
intrauterine gestational sac (with positive cardiac pulsa-
tions on ultrasound) at 35 or 45 days after ET was con-
sidered to indicate a clinical pregnancy. Other rates were
also calculated: the implantation rate (IR) = number of
sacs (both within and outside the uterine cavity)/the
number of transferred embryos; the fertilization rate =
the number of 2PN oocytes/the number of oocytes re-
trieved; and the cleavage rate = the number of 2PN
cleavage-stage embryos/the number of 2PN oocytes.
Statistical analysis
The continuous variables are described using means and
standard deviations (SDs) or medians and interquartile
ranges (IQRs). The categorical variables are described as
percentages of the total. Student’s t-test or the Mann–
Whitney U test were applied for single comparisons, and
one-way analysis of variance (ANOVA) followed by the
least significant difference (LSD) t test or the Kruskal-
Wallis (KW) test followed by all pairwise multiple
comparisons were used for multiple comparisons of the
continuous variables based on the normality of the distri-
bution. For categorical variables, the chi-square test or
Fisher's exact test was performed.
Because the relationship between serum progesterone
levels and pregnancy rates was assumed to be non-linear
[19], the patients in the day 3 and day 5 ET groups were
divided into the following eight distinct groups for ana-
lyses according to their serum progesterone levels on the
day of hCG: <0.50, 0.50-074, 0.75-0.99, 1.00-1.24, 1.25-
1.49, 1.50-1.74, 1.75-1.99 and ≥2.00 ng/ml [5, 6]. To assess
the association between PE and CPRs and determine the
thresholds at which PE has a detrimental effect on CPRs,
CPRs were calculated for each group and subjected to a
Mantel-Haenszel test for trend analysis. Furthermore, the
odds ratios (ORs) and 95 % confidence intervals (CIs) of
the CPRs were calculated to confirm the thresholds by
comparing each group to the group with the lowest pro-
gesterone level (<0.50 ng/ml). Pairwise comparisons were
also made between adjacent groups, as follows: <0.50 and
0.50-0.74 ng/ml, 0.50-0.74 and 0.75-0.99 ng/ml, 0.75-0.99
and 1.00-1.24 ng/ml, 1.00-1.24 and 1.25-1.49 ng/ml, 1.25-
1.49 and 1.50-1.74 ng/ml, 1.50-1.74 and 1.75-1.99 ng/ml,
and 1.75-1.99 and ≥2.00 ng/ml. Moreover, the develop-
mental stage of the transferred embryos (cleavage versus
blastocyst stage), PE (defined as an unordered categorical
variable according to progesterone levels: <0.50, 0.50-074,
0.75-0.99, 1.00-1.24, 1.25-1.49, 1.50-1.74, 1.75-1.99
and ≥2.00 ng/ml) and the interaction terms between
them were examined in multivariate logistic regression
analyses and evaluated together with other confounders to
assess the effect of the developmental stage of the trans-
ferred embryos on the association PE with CPR. The con-
founders included female age, BMI, gonadotropin dose,
the number of retrieved oocytes, the number of trans-
ferred embryos, the number of top-quality transferred
embryos, and serum E2 levels on the day of hCG ad-
ministration [27, 28].
After appropriate progesterone threshold levels were
determined for the day 3 and day 5 ET groups, the
serum progesterone levels were subdivided based on the
threshold and were subjected to multivariate logistic re-
gression analyses while controlling for other con-
founders to more accurately determine the effect of
serum PE on CPRs. Additionally, the patients in these
two groups were classified into several subgroups ac-
cording to each group’s progesterone cut-off level. The
demographic and clinical characteristics of the individ-
uals in these subgroups were then compared.
Results
Patient characteristics
The included patients’ baseline characteristics are shown
in Table 1. A total of 10,864 patients underwent day 3
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ET, and a total of 1146 patients underwent day 5 ET in
IVF/ICSI/IVF + ICSI cycles. The median (IQR) bFSH
levels of these patients were 7.16 (2.5) and 6.57 (2.0)
IU/L, respectively. A total of 84.3 % patients in the day
3 ET group and 88.1 % patients in the day 5 ET group
were in their first IVF/ICSI cycles. Several relatively clear
causes of infertility were present in the patients in the day
3 and day 5 ET groups, including tubal pathology (44.5
and 58.5 %, respectively), male factors (27.5 and 29.8 %,
respectively), advanced age (≥35 years, 11.1 and 14.6 %, re-
spectively), PCOS (6.2 and 11.5 %, respectively), and endo-
metriosis (3.5 and 3.3 %, respectively).
Table 2 presents the clinical, oocyte and embryo pa-
rameters from controlled ovarian stimulation to ET. The
median (IQR) duration and dose of gonadotropin were
11.0 (2.0) days and 2100 (1275) IU, respectively, in the
day 3 group and 11.0 (2.0) days and 1637.5 (787) IU, re-
spectively, in the day 5 group. The mean (±SD) level of
serum progesterone, the E2 level on the day of hCG, and
the median (IQR) number of retrieved oocytes were
0.83 ± 0.44 ng/ml, 4421.8 ± 2570 pg/ml and 10 (7), re-
spectively, in the day 3 group; these values were much
higher in the day 5 group (1.03 ± 0.43 ng/ml, 7696.2 ±
2659.7 pg/ml and 18 (5), respectively). Double ET oc-
curred in most of the individuals in the day 3 ET group
(87 %), and single blastocyst-stage ET occurred in most
of the individuals in the day 5 ET group (91.4 %).
The relationship between serum progesterone levels and
clinical pregnancy rates
The relationships between serum progesterone levels on
the day of hCG administration and CPRs in the day 3
ET group are shown in Fig. 1.
Serum progesterone levels were inversely related to
CPRs in the day 3 ET group, as shown in Fig. 1a (p <
0.0001 for overall trend). A decrease in CPRs was ob-
served when the serum progesterone level was ≥1.0 ng/
ml, and an additional reduction was observed when the
serum progesterone level was ≥1.5 ng/ml. By compar-
ing each group to the group with the lowest progester-
one level (<0.5 ng/ml), the ORs (95 % CIs) of CPRs
were calculated (Fig. 1b). The CPRs of these five groups
with progesterone levels ≥1.0 ng/ml were significantly
lower than the CPRs of the group with the lowest pro-
gesterone level (<0.5 ng/ml). Furthermore, when the
0.75-0.99 ng/ml group was compared with the 1.00-
1.24 ng/ml group (49.8 % VS. 45.5 %, p = 0.009) and the
1.25-1.49 ng/ml group was compared with the 1.50-
1.74 ng/ml group (45.5 % VS. 35.3 %, p = 0.002), the
differences were statistically significant. These data sug-
gest that progesterone began to have a detrimental
Table 1 Patients’ baseline characteristics
Parameter Day 3 ET Day 5 ET
(n = 10,864) (n = 1146)
Age (years) 31.3 ± 5.1 29.7 ± 4.5
BMI (kg/m2) 22.0 (3.0) 22.0 (4.5)
bFSH (IU/L) 7.16 (2.5) 6.57 (2.0)
Duration of infertility (years) 3 (4) 3 (3)
Primary infertility (%) 49.2 55.2
Second infertility (%) 50.8 44.8
First treatment cycle (%) 84.3 88.1
Cause of infertility (%)
tubal pathology 44.5 58.5
male factors 27.5 29.8
advanced age (≥35 years) 11.1 14.6
PCOS 6.2 11.5
endometriosis 3.5 3.3
pelvic pathology 6.5 6.5
others 3.8 4.1




IVF + ICSI 1.4 2.2
Stimulation protocol (%)
GnRH-a long protocol 82.8 93.5
GnRH-a prolonged (modified) protocol 11.1 5.8
Note: ART: assisted reproductive technology; IVF + ICSI: IVF + rescue ICSI or
IVF + late ICSI; GnRH-a: gonadotropin-releasing hormone agonist; PCOS:
polycystic ovary syndrome
Table 2 Clinical/oocyte/embryo parameters from ovarian
stimulation to embryo transfer
Parameter Day 3 ET Day 5 ET
(n = 10,864) (n = 1146)
Duration of stimulation (days) 11.0 (2.0) 11.0 (2.0)
Total dose of Gn (IU) 2100 (1275) 1637.5 (787)
Serum progesterone (ng/ml), hCG day 0.83 ± 0.44 0.99 ± 0.43
Serum E2 (pg/ml), hCG day 4421.8 ± 2570.0 7696.2 ± 2659.7
Serum LH (IU/L), hCG day 1.88 (1.13) 1.46 (0.87)
Endometrial thickness (mm), hCG day 12.0 (1.8) 12.0(1.3)
Oocytes retrieved (n) 10 (7) 18 (5)
2PN oocytes (n) 6 (5) 14 (4)
2PN cleavage embryos (n) 6 (5) 13 (4)
Available embryos (n) 5 (4) 9 (4)
ET with a single embryo (%) 1.3 91.4
ET with two embryos (%) 87 8.6
ET with more than two embryos (%) 11.7 /
Note: Values are the mean ± SD or median (IQR) unless otherwise noted; hCG:
human chorionic gonadotropin; Gn: gonadotropin; E2: estrogen; LH: luteinizing
hormone; ET: embryo transfer
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effect on the probability of pregnancy in day 3
cleavage-stage ET cycles once the serum progesterone
level reached 1.0 ng/ml. When the progesterone con-
centration reached 1.5 ng/ml, the detrimental effect ap-
peared to worsen.
The relationships between serum progesterone levels
and CPRs in the day 5 ET group are shown in Fig. 2.
The patients’ serum progesterone levels were inversely
associated with CPRs, as shown in Fig. 2a (p = 0.0076 for
the overall trend). CPRs decreased with gradually higher
Fig. 1 Relationship between serum progesterone levels and CPRs in the day 3 ET group (a) Relationship between serum progesterone levels and
CPRs, (b) CPRs according to serum progesterone levels. *p < 0.05 for comparison with the previous progesterone group; data are expressed as the
OR (95 % CI) for each serum progesterone group compared with the group with the lowest progesterone level (<0.5 ng/ml); OR: odds ratio; CI:
confidence interval
Fig. 2 Relationship between serum progesterone levels and CPRs in the day 5 ET group (a) Relationship between serum progesterone levels and
CPRs, (b) CPRs according to serum progesterone levels. *p < 0.05 for comparison with the previous progesterone group; data are expressed as
the OR (95 % CI) for each serum progesterone group compared with the group with the lowest progesterone level (<0.5 ng/ml); OR: odds
ratio; CI: confidence interval
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levels of serum progesterone, especially when the serum
progesterone level was ≥1.75 ng/ml. The ORs (95 % CI)
of CPRs for each of the groups compared with the group
with the lowest progesterone level (<0.5 ng/ml) are
shown in Fig. 2b. Statistically significant reductions in
CPRs were only observed in the 1.75-1.99 (OR: 0.307
[0.146-0.646], p = 0.001) and ≥2 ng/ml groups (OR:
0.414 [0.184-0.934], p = 0.029). Moreover, when adjacent
groups were compared, the CPRs differed significantly
only between the 1.5-1.74 and 1.75-1.99 ng/ml groups
(38.9 % VS. 19.1 %, p = 0.019 and 42.6 % VS. 22.2 %, p =
0.021, respectively). These results imply that a serum
progesterone concentration of 1.75 ng/ml was likely to
be the cut-off level at which progesterone has an adverse
impact on clinical pregnancy in IVF cycles with day 5
blastocyst-stage ETs.
Multivariate analysis of factors associated with clinical
pregnancy
A multivariate logistic regression analysis showed that
several factors were significantly associated with CPRs
(Table 3). In the day 3 ET group, serum PE was nega-
tively associated with CPRs (OR: 0.874 [0.823-0.929], p
< 0.001), whereas the number of top-quality transferred
embryos was positively associated with CPRs (OR: 1.073
[1.001-1.150], p = 0.047). The results were similar for the
day 5 ET group (p < 0.05 for each comparison); however,
female age was negatively associated with CPRs (OR:
0.770 [0.606-0.980], p = 0.03).
Interaction between the developmental stage of the
transferred embryos and the effect of PE on CPRs
To assess whether PE’s effect on clinical pregnancy was
influenced by the developmental stage of the transferred
embryos, an interaction term of developmental stage of
transferred embryos and PE was included in the multi-
variate analyses (Table 4). Female age, PE, the develop-
mental stage of the transferred embryos and the number
of transferred top-quality embryos were all significantly
related to the CPR. However, the interaction term (de-
velopmental stage of transferred embryos*PE) was not
statistically significant (p > 0.05 for all progesterone
levels), which also could not support the possible influ-
ence of the transferred embryos on PE’ effect on CPRs
Results of comparisons between subgroups
Demographic and clinical characteristics were compared
among the subgroups within the day 3 ET group
(Table 5) and the day 5 ET group (Table 6).
In the day 3 ET group (Table 5), BMI and bFSH levels
were lower in the <1 ng/ml subgroup than in the ≥1.0 ng/
ml subgroups, whereas the dose of gonadotropin; the
numbers of 2PN oocytes, cleavage-stage embryos and
available embryos; and female age were higher. The
serum LH levels, endometrial thickness on the day of
hCG administration and cleavage rates were lower in
the ≥1.5 ng/ml subgroup than in the <1.5 ng/ml subgroups.
When serum progesterone was elevated, the serum E2
levels and the number of retrieved oocytes were increased;
however, fertilization rates, CPRs and IRs were significantly
decreased.
In the day 5 ET group (Table 6), basal FSH levels,
serum LH levels, fertilization rates and cleavage rates
did not differ significantly between the two subgroups.
The larger number of retrieved oocytes and higher
serum E2 levels observed in the ≥1.75 ng/ml subgroup
Table 3 Multivariate analysis of factors related to clinical pregnancy
Factors Day 3 ET Day 5 ET
OR (95 % CI) p-value OR (95 % CI) p-value
Female age(years) / / 0.770 (0.606-0.980) 0.034
PEa, hCG day 0.874 (0.823-0.929) <0.001 0.419 (0.237-0.742) 0.003
No. of transferred TQEs 1.073 (1.001-1.150) 0.047 1.331 (1.045-1.696) 0.021
Note: TQE: top-quality embryo; athree levels of PE were defined in the day 3 ET group: <1 ng/ml, 1–1.49 ng/ml, and ≥1.5 ng/ml; two levels of PE were defined in
the day 5 ET group: <1.75 ng/ml and ≥1.75 ng/ml. OR: odds ratio; CI: confidence interval
Table 4 Interaction between the developmental stage of the
transferred embryos and the effect of PE on CPRs
Factors OR (95 % CI) p-value
Female age (years) 0.930(0.872-0.993) 0.031
No. of transferred TQE 1.102(1.031-1.179) 0.004
Developmental stage 0.842(0.718-0.987) 0.004
Progesterone elevation (ng/ml)ª <0.001









Note: TQE: top-quality embryo; OR: odds ratio; CI: confidence interval.
developmental stage: cleavage versus blastocyst stage, PEª was defined as
an unordered categorical variable according to progesterone levels: <0.50,
0.50-074, 0.75-0.99, 1.00-1.24, 1.25-1.49, 1.50-1.74, 1.75-1.99 and ≥2.00 ng/ml. The
95 % CIs of developmental stage bPE were all covered 1
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may indicate that this subgroup had a better ovarian
response. However, this subgroup presented signifi-
cantly lower IRs (29.5 % VS. 46.2 %, p = 0.002) and
CPRs (31.3 % VS. 41.4 %, p < 0.001) compared with
the <1.75 ng/ml subgroup with more transferred em-
bryos. In addition, female age was significantly higher
in the ≥1.75 ng/ml subgroup (31.5 ± 5.2 VS. 29.5 ± 4.4 y, p
= 0.002).
Discussion
This study showed that PE on the day of hCG adminis-
tration decreased CPRs in both cleavage- and blastocyst-
stage ET cycles using gonadotropin and GnRH agonist
for controlled ovarian stimulation. In the day 3 ET cy-
cles, a serum progesterone concentration of 1.0 ng/ml
had a detrimental effect on CPRs. This detrimental effect
worsened when the progesterone concentration reached
1.5 ng/ml. However, in the day 5 blastocyst-stage ET cy-
cles, the detrimental effect did not appear until the pro-
gesterone concentration reached 1.75 ng/ml. The
negative associations of PE with CPRs in both the day 3
and day 5 ET groups were the same after adjusting for
confounders using multivariate analysis. Furthermore,
the non-significant value of the test of the interaction
between the developmental stage of the transferred em-
bryos and PE with CPRs further confirmed that PE on
the day of hCG administration was negatively associated
with clinical pregnancy, regardless of the developmental
stage of the transferred embryos.
Our results reaffirm the conclusions of previous retro-
spective studies that serum progesterone elevation on
the day of hCG administration inversely impacts the preg-
nancy outcomes of patients undergoing IVF [1, 6, 10, 11].
In our study of more than 10,000 day 3 ET patients, we
found that the detrimental effect of PE began at a thresh-
old level 1.0 ng/ml and worsened when the level reached
1.5 ng/ml, which was similar to the findings of a recent
meta-analysis [1] showing that progesterone levels (range:
0.8–1.1 ng/ml) have detrimental effects that worsen when
the progesterone concentration reaches 1.2 ng/ml. Add-
itionally, our study provides support for the nonlinear re-
lationship between the progesterone levels on the day of
hCG administration and pregnancy outcomes in fresh IVF
cycles [1, 6].
Clinicians have utilized different strategies for control-
ling PE with the aim of avoiding its possible detrimental
effects in fresh IVF cycles. Such PE control strategies in-
clude employing a mild stimulation protocol to achieve
Table 5 Comparisons of demographic and clinical characteristics between subgroups of the day 3 ET group
Parametera Serum P levels (ng/ml), day 3 ETb
<1.0 1.0-1.49 ≥1.5
No. of fresh cycles 7627 2373 846
Female age (years) 31.1 ± 5.1 31.8 ± 5.0* 32.1 ± 5.1
BMI (kg/m2) 22.7 ± 3.2 22.3 ± 3.0* 22.1 ± 3.0
Basal FSH (IU/L) 7.7 ± 2.9 7.3 ± 2.4* 7.2 ± 2.2
Total dose of Gn (IU) 2201.2 ± 940.7 2268.6 ± 879.3* 2357.1 ± 890.1*
Serum E2 (pg/ml), hCG day 3941.8 ± 2118.6 5321.0 ± 2353.8* 6201.8 ± 4598.0*
Serum LH (IU/L), hCG day 2.0 ± 1.3 1.9 ± 1.4 1.72 ± 1.9*
Endometrial thickness (mm), hCG day 12.3 ± 2.4 12.2 ± 2.5 12.0 ± 2.4*
No. of oocytes retrieved 9.3 ± 4.4 11.1 ± 4.6* 12.0 ± 4.8*
No. of 2PN oocytes 6.4 ± 3.3 7.5 ± 3.5* 7.8 ± 4.8
No. of 2PN cleavage embryos 6.4 ± 3.3 7.5 ± 3.5* 7.8 ± 4.8
No. of available embryos 5.0 ± 2.8 5.7 ± 3.0* 5.9 ± 3.2
Fertilization rate (%) 69 67.4* 65.1*
Cleavage rate (%) 97.8 97.7 97.3**
No. of transferred embryos 2.10 ± 0.34 2.12 ± 0.34* 2.14 ± 0.39
No. of transferred top-quality embryos 1.97 ± 0.55 2.00 ± 0.53** 2.02 ± 0.56*
Implantation rate (%) 36.3 31.6* 26*
CPR (%) 50.4 45.5* 36.2*
Note: Day 3 ET subgroups according progesterone cut-off levels: <1 ng/ml, 1–1.49 ng/ml, and ≥1.5 ng/ml. P = progesterone
aAll values are presented as the mean ± SD or count (%)
bDifferences between subgroups were determined using ANOVA followed by the LSD-t test or the Kruskal-Wallis (KW) test and subsequent pairwise multiple
comparisons for continuous variables and the chi-square test or Fisher’s exact test for categorical variables
*p < 0.01 compared with the previous subgroup
**p < 0.05 compared with the previous subgroup
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lower estradiol levels [19] or an earlier hCG trigger in
high responders to avoid PE in the late follicular phase
[20]. Other strategies that have been used to increase
the probability of pregnancy in cases of PE in fresh IVF
cycles included canceling fresh ETs and replacing the
fresh embryos with frozen-thawed embryos in natural
cycles. However, a recent retrospective analysis revealed
that the incidence of PE (serum progesterone ≥1.57 ng/
ml) in frozen-thawed embryo-transferred natural cycles
was similar to that in fresh stimulated cycles [29].
Replacing cleavage-stage embryos with blastocyst-stage
embryos prior to transfer has also been advocated since
a previous study found that PE on the day of hCG ad-
ministration decreased pregnancy rates in day 3 single
ET cycles but not in day 5 single blastocyst transfer cy-
cles. It was assumed that the endometrium had already
significantly recovered from the impairment caused by
supra-physiological steroid concentrations on the fifth
luteal day [7, 21]. Although other studies have supported
this hypothesis [9, 30], the reliability of this procedure
still requires confirmation. In the present study, PE
adversely affected CPRs when the progesterone level
was ≥1.75 ng/ml in the day 5 blastocyst-stage ET group, a
finding that is in agreement with previous suggestions that
PE could impair IVF outcomes even with blastocyst trans-
fers [8, 13, 22]. Furthermore, our interaction test did not
reveal a link between the developmental stage of the
transferred embryos and the effect of PE on clinical
pregnancy [1].
In our study, we also used multivariate analysis to as-
sess the detrimental effects of PE on CPRs [31] because
parameters other than PE are closely related to IVF
pregnancy outcomes [5, 32]. The results of this analysis
showed that the number of top-quality transferred em-
bryos had a positive effect on CPRs in both the day 3
and day 5 ET groups. Female age had a negative effect
only in the day 5 ET group. In accordance with this re-
sult, female age is considered an independent factor re-
lated to clinical pregnancy because of age-related changes
in the ovarian reserve, oocyte quality, embryo quality, and
the uterine environment [33, 34]. However, oocyte num-
ber, which has been demonstrated to be correlated with
PE [28] and strongly related to the probability of preg-
nancy and live birth [1, 3, 5, 6], was not confirmed to
be related to CPRs in our study.
In IVF cycles, the luteal-phase endometrium is altered
by the supra-physiological steroid concentration induced
by ovarian hyperstimulation [21]. When the progester-
one level is >1.5 ng/ml on the day of hCG administra-
tion, differences in gene expression in the endometrium
occur after 36 h [35]. Our data also indicated that CPRs
and implantation rates were obviously reduced when the
Table 6 Comparison of demographic and clinical characteristics between subgroups of the day 5 ET group
Parametera Serum P levels (ng/ml), day 5 ET P-value*
<1.75 ≥1.75
No. of fresh cycles 1066 80
Female age (years) 29.5 ± 4.4 31.5 ± 5.2 0.002
BMI (kg/m2) 22.60 ± 3.31 21.95 ± 2.59 0.036
Basal FSH (IU/L) 6.61 ± 1.57 6.53 ± 1.83 NS
Total dose of Gn (IU) 1760.0 ± 635.5 2114.1 ± 680.7 <0.001
Serum E2 (pg/ml), hCG day 7583.3 ± 2595.8 9200.6 ± 3038.1 <0.001
Serum LH (IU/L), hCG day 1.6 ± 0.7 1.5 ± 0.7 NS
Endometrial thickness (mm), hCG day 12.2 ± 2.3 12.1 ± 2.5 NS
No. of oocytes retrieved 17.9 ± 5.0 19.7 ± 4.9 0.003
No. of 2PN oocytes 13.1 ± 3.8 14.4 ± 4.3 0.014
No. of 2PN cleavage embryos 12.9 ± 3.8 14.2 ± 4.3 0.003
No. of available embryos 9.7 ± 3.8 9.9 ± 4.8 0.031
Fertilization rate (%) 74.4 73.5 NS
Cleavage rate (%) 98.5 99.1 NS
No. of transferred embryos 1.08 ± 0.27 1.19 ± 0.39 0.017
ET with top-quality blastocyst (%) 58.7 52.7 NS
Implantation rate (%) 46.2 29.5 0.002
CPR (%) 41.4 21.3 <0.001
Note: Day 5 ET subgroups according progesterone cut-off levels: <1.75 ng/ml, ≥1.75 ng/ml; NS = not statistically significant
aAll values are presented as the mean ± SD or count (%)
*Differences between subgroups were determined using Student’s t-test or the Mann–Whitney U test for continuous variables and the chi-square test or Fisher’s
exact test for categorical variables
Huang et al. Reproductive Biology and Endocrinology  (2015) 13:82 Page 8 of 10
progesterone level was >1.5 ng/ml in the day 3 ET
group. A functional genomics analysis of the endomet-
rium also confirmed that gene expression was altered in
the endometrium as a result of PE on the day of hCG
administration [16, 17]. In stimulated cycles, advanced
endometrial maturation induced by PE may be related to
the earlier closure of the implantation window and a re-
duction in pregnancy rates [14, 15]. Taken together, these
observations indicate that endometrial receptivity is im-
paired by elevated progesterone, which may explain the
poor IVF pregnancy outcomes. However, oocyte quality
may not be affected [1, 18], as our data indicate that the
fertilization and cleavage rates were not significantly dif-
ferent in the day 5 ET subgroups.
Comparisons between the subgroups of the day 3 and
day 5 ET groups revealed that PE was associated with in-
creased gonadotropin dose [1], oocyte number and E2
levels [5, 8, 11], which is in agreement with previous stud-
ies. These results may have occurred because each individ-
ual follicle contributes to the progesterone concentration
in the circulation [36].
Interestingly, the cut-off levels for PE-induced impair-
ment were different in the day 3 and day 5 ET groups in
our study. Because the sample size of the day 3 ET group
was sufficiently large (it contained more than 10,000 pa-
tients) and it included all patients regardless ovarian re-
sponse [5, 6, 31], the cut-off levels (1.0 and 1.5 ng/ml) of
the day 3 ET group may significantly represent the
thresholds in the general population. However, the cut-
off levels (1.75 ng/ml) of the day 5 ET group may be
limited because of its smaller sample size (n = 1146).
Moreover, the day 5 blastocyst-stage ET group tended
to include good ovarian responders with high serum
steroid levels as a result of the criteria for blastocyst
transfer in our study.
The same progesterone assay used in our study and
the quality control of the assay in our individual labora-
tory ensured the consistency of our progesterone meas-
urement and minimized any variability in our assay [37].
However, because the assays in different institutes vary
[3], our thresholds may differ from those of other studies
that used different assays. Overall, our findings have the
following clinical implications: serum progesterone levels
should be controlled during controlled ovarian stimula-
tion to avoid the detrimental effects of PE, replacing
cleavage-stage embryos with blastocysts before transfer
is not effective for avoiding the detrimental effects of PE,
and utilizing a multivariate approach to assess the effects
of PE in a given population and identifying specific cut-
offs for that population in clinical practice is important.
In conclusion, this study shows that PE on the day of
hCG administration is associated with decreased CPRs
in GnRH agonist IVF/ICSI cycles regardless of the devel-
opmental stage of ET (cleavage versus blastocyst stage).
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